Ian Clark has served as a member of the Board of Directors since August 2020. Mr. Clark most recently served as Chief Executive Officer and Board member of Genentech, Inc. Prior to that, Mr. Clark held several senior management positions at Genentech/Roche, including Head of Global Product Strategy, Executive Vice President, Commercial Operations, and Senior Vice President and General Manager of BioOncology. Prior to that, Mr. Clark spent 23 years in the biopharmaceutical industry in senior roles at Novartis International AG, Sanofi S.A., Ivax Pharmaceuticals, and G.D. Searle. Mr. Clark serves as a member of the Boards of Directors of Takeda Pharmaceutical Company Limited, BioMarin Pharmaceutical Inc., Kyverna Therapeutics, Inc., Corvus Pharmaceuticals, Inc., Guardant Health, Inc., and GoodRx Holdings, Inc. Previously, he was on the Boards of AVROBIO, Inc., Shire Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Forty Seven Inc., and Kite Pharma, Inc. Mr. Clark is currently an advisor to KKR & Co. Inc., and previously served on the Board of the Biotechnology Industry Organization (BIO) and as a member of the 12th District Economic Advisory Council (EAC) of the Federal Reserve. Mr. Clark received his B.S. in Biological Sciences and an Honorary Doctorate of Science from Southampton University in the United Kingdom.
What is Ian T. Clark's net worth?
The estimated net worth of Ian T. Clark is at least $246.37 thousand as of December 5th, 2025. Clark owns 9,851 shares of Olema Pharmaceuticals stock worth more than $246,374 as of February 6th. This net worth estimate does not reflect any other investments that Clark may own. Learn More about Ian T. Clark's net worth.
How do I contact Ian T. Clark?
Has Ian T. Clark been buying or selling shares of Olema Pharmaceuticals?
Ian T. Clark has not been actively trading shares of Olema Pharmaceuticals during the past quarter. Most recently, Ian T. Clark sold 264,800 shares of the business's stock in a transaction on Friday, December 19th. The shares were sold at an average price of $29.73, for a transaction totalling $7,872,504.00. Learn More on Ian T. Clark's trading history.
Who are Olema Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Olema Pharmaceuticals?
During the last twelve months, insiders at the sold shares 16 times. They sold a total of 790,501 shares worth more than $22,257,272.41. The most recent insider tranaction occured on January, 20th when Director Cyrus Harmon sold 10,000 shares worth more than $268,800.00. Insiders at Olema Pharmaceuticals own 16.4% of the company.
Learn More about insider trades at Olema Pharmaceuticals. Information on this page was last updated on 1/20/2026.
